Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Qiong Du
Observed names:
DU Qiong,
Du, Qiong
Institutions:
Kunming University of Science and Technology,
Shanghai Medical College of Fudan University,
China Three Gorges University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Kunming University of Science and Technology,
Shanghai Medical College of Fudan University,
China Three Gorges University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0000-0003-4830-9704
Observed ORCID:
0000-0003-4830-9704
OpenAlex ID:
A5100940452
The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/β-Catenin Signaling Pathway
2017
·
Bo Yu
, Xuan Ye
, et al.
·
Cellular Physiology and Biochemistry
·
100
Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
2023
·
Rong Tang
, Jin Xu
, et al.
·
Cell Reports Medicine
·
86
Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma
2017
·
Bo Yu
, Qiong Du
, et al.
·
Oncotarget
·
77
PDF
Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3.
2017
·
Qiong Du
, Bin Zhu
, et al.
·
PubMed
·
73
SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer
2021
·
Rui Xu
, Xin Luo
, et al.
·
Frontiers in Oncology
·
69
PDF
Role of mitochondrial permeability transition in human hepatocellular carcinoma Hep-G2 cell death induced by rhein
2013
·
Qiong Du
, Xiao-Lan Bian
, et al.
·
Fitoterapia
·
52
lncRNA SLC16A1-AS1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer
2019
·
Hong Yue Liu
, Sheng Rong Lu
, et al.
·
Journal of Investigative Medicine
·
51
Exosomal miR-30a and miR-222 derived from colon cancer mesenchymal stem cells promote the tumorigenicity of colon cancer through targeting MIA3
2021
·
Qiong Du
, Xuan Ye
, et al.
·
Journal of Gastrointestinal Oncology
·
48
PDF
Landscape and progress of global COVID-19 vaccine development
2021
·
Hui-Yao Huang
, Shu-Hang Wang
, et al.
·
Human Vaccines & Immunotherapeutics
·
46
Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
2022
·
Zihan Guo
, Yunlan Ding
, et al.
·
Journal of Clinical Pharmacy and Therapeutics
·
43
PDF
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism
2025
·
Rong Tang
, Zifeng Zhang
, et al.
·
Gastroenterology
·
42
Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
2023
·
Wensheng Liu
, Qiong Du
, et al.
·
Frontiers in Pharmacology
·
41
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer: a systematic review
2022
·
Linhui Zhu
, Mengmeng Wang
, et al.
·
Annals of Translational Medicine
·
32
PDF
CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug–gene interaction network
2024
·
Youjun She
, Zihan Guo
, et al.
·
Frontiers in Pharmacology
·
27
PDF
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients
2016
·
Qiong Du
, Qing Zhai
, et al.
·
Journal of Oncology Pharmacy Practice
·
21
Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients
2021
·
Linhui Zhu
, Huan Li
, et al.
·
International Journal of Clinical Oncology
·
19
PDF
Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study
2024
·
Zihan Guo
, Yunlan Ding
, et al.
·
Pharmaceuticals
·
15
PDF
Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
2025
·
Wensheng Liu
, Feifei Gao
, et al.
·
Frontiers in Pharmacology
·
12
PDF
Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system
2023
·
Shuohan Huang
, Zihan Guo
, et al.
·
Expert Opinion on Drug Safety
·
12
PDF
Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial
2022
·
Xiaowei Zheng
, Haiying Ding
, et al.
·
Pain and Therapy
·
12
PDF
Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years
2022
·
Ping Zhang
, Donghui Lao
, et al.
·
Frontiers in Immunology
·
11
PDF
Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma
2024
·
Rong Tang
, Zifeng Zhang
, et al.
·
Computational and Structural Biotechnology Journal
·
10
Systematic Characterization of DNA Methyltransferases Family in Tumor Progression and Antitumor Immunity
2024
·
Fengru Huang
, Xinyi Wu
, et al.
·
Technology in Cancer Research & Treatment
·
9
SKF96365 impedes spinal glutamatergic transmission-mediated neuropathic allodynia
2022
·
Qiru Wang
, Yang Zhang
, et al.
·
Korean Journal of Physiology and Pharmacology
·
8
PDF
Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma
2025
·
Jiefeng Luo
, Zhengxiong Li
, et al.
·
Human Vaccines & Immunotherapeutics
·
7
Show more works
View as search
Works count:
65
Citation count:
1,027
H-index:
16
I10-index:
22
Year
Topic
Type